The IMPACT Study

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study

EK Bancroft, EC Page, J McHugh, S Thomas, N Taylor, J Pope, DG Evans, J Rothwell, EM Grindedal, L Maehle, P James, J McKinley, L Mascarenhas, L Side, T Thomas, ME van Leerdam, CJ van Asperen, LALM Kiemeney, J Ringelberg, M Vlaming

2026-01-01

Background and objective BRCA1 and BRCA2 pathogenic germline variants (PGVs) are associated with higher risk of prostate cancer (P..

A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study

EK Bancroft, EC Page, MN Brook, S Thomas, N Taylor, J Pope, J McHugh, AB Jones, Q Karlsson, S Merson, KR Ong, J Hoffman, C Huber, L Maehle, EM Grindedal, A Stormorken, DG Evans, J Rothwell, F Lalloo, AF Brady

2021-11-01

Background: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH..

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

EC Page, EK Bancroft, MN Brook, M Assel, M Hassan Al Battat, S Thomas, N Taylor, A Chamberlain, J Pope, HN Raghallaigh, DG Evans, J Rothwell, L Maehle, EM Grindedal, P James, L Mascarenhas, J McKinley, L Side, T Thomas, C van Asperen

2019-12-01

Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluatin..

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

C Mikropoulos, CGH Selkirk, S Saya, E Bancroft, E Vertosick, T Dadaev, C Brendler, E Page, A Dias, DG Evans, J Rothwell, L Maehle, K Axcrona, K Richardson, D Eccles, T Jensen, PJ Osther, CJ Van Asperen, H Vasen, LA Kiemeney

2018-01-01

Background:Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa..

Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men

E Killick, R Morgan, F Launchbury, E Bancroft, E Page, E Castro, Z Kote-Jarai, A Aprikian, I Blanco, V Clowes, S Domchek, F Douglas, D Eccles, DG Evans, M Harris, J Kirk, J Lam, G Lindeman, G Mitchell, N Pachter

2013-06-24

Controversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in ..